Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURANASDAQ:ETONNASDAQ:IZTCNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.26-1.7%$6.08$4.84▼$12.38$264.18M0.43205,859 shs313,994 shsETONEton Pharmaceuticals$17.07-1.6%$14.55$3.18▼$18.41$457.78M1.22184,499 shs335,618 shsIZTCInvizyne Technologies$12.54-3.6%$12.15$8.50▼$23.00$78.40MN/A37,647 shs39,984 shsTSHATaysha Gene Therapies$2.34+0.9%$1.67$1.05▼$4.32$475.73M0.92.81 million shs2.30 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-1.68%-4.03%-0.75%-33.59%-26.74%ETONEton Pharmaceuticals-1.61%+2.86%+37.11%+0.53%+380.85%IZTCInvizyne Technologies-3.61%+15.58%+15.05%-25.00%+1,253,999,900.00%TSHATaysha Gene Therapies+0.86%+17.00%+87.95%+46.25%-2.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.1516 of 5 stars3.62.00.00.02.12.50.0ETONEton Pharmaceuticals2.7333 of 5 stars3.53.00.00.03.90.80.6IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATSHATaysha Gene Therapies1.9259 of 5 stars3.50.00.00.02.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.75332.51% UpsideETONEton Pharmaceuticals 3.00Buy$27.6762.08% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ATSHATaysha Gene Therapies 3.00Buy$6.43174.73% UpsideCurrent Analyst Ratings BreakdownLatest IZTC, AURA, ETON, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.004/28/2025TSHATaysha Gene TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.004/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/19/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.003/19/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $24.003/19/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.002/27/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AETONEton Pharmaceuticals$39.01M11.73$0.00 per share4,502.79$0.60 per share28.45IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ATSHATaysha Gene Therapies$8.33M57.58N/AN/A$0.40 per share5.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/15/2025 (Estimated)ETONEton Pharmaceuticals-$940K-$0.15N/A34.14N/A-15.81%-36.29%-16.84%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ATSHATaysha Gene Therapies-$111.57M-$0.363.71N/AN/A-229.67%-106.36%-49.16%5/15/2025 (Estimated)Latest IZTC, AURA, ETON, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.45N/AN/AN/AN/AN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08N/AN/AN/A$1.48 millionN/A5/8/2025Q1 2025ETONEton Pharmaceuticals$0.05$0.07+$0.02-$0.06$14.33 millionN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 million2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47ETONEton PharmaceuticalsN/A1.511.41IZTCInvizyne TechnologiesN/AN/AN/ATSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%ETONEton Pharmaceuticals27.86%IZTCInvizyne TechnologiesN/ATSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%ETONEton Pharmaceuticals16.03%IZTCInvizyne TechnologiesN/ATSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableIZTCInvizyne TechnologiesN/A6.25 millionN/AN/ATSHATaysha Gene Therapies180205.06 million199.41 millionOptionableIZTC, AURA, ETON, and TSHA HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 13 at 6:54 AM | marketbeat.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on ThursdayMay 13 at 1:29 AM | americanbankingnews.comDAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 10, 2025 | marketbeat.comTaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15May 8, 2025 | globenewswire.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 8, 2025 | marketbeat.comWill Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should KnowMay 6, 2025 | zacks.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?May 5, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from BrokeragesMay 5, 2025 | americanbankingnews.comAcuta Capital Partners LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 4, 2025 | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 11.41%May 3, 2025 | aaii.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsMay 2, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Makes New $8.65 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 1, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 30, 2025 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 29, 2025 | marketbeat.comAvoro Capital Advisors LLC Buys 1,349,999 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23, 2025 | marketbeat.comB Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)April 23, 2025 | marketbeat.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Up 16.13%April 22, 2025 | aaii.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co.April 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, AURA, ETON, and TSHA Company DescriptionsAura Biosciences NASDAQ:AURA$5.26 -0.09 (-1.68%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$5.82 +0.56 (+10.72%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$17.07 -0.28 (-1.61%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$17.33 +0.26 (+1.52%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Invizyne Technologies NASDAQ:IZTC$12.54 -0.47 (-3.61%) As of 05/12/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Taysha Gene Therapies NASDAQ:TSHA$2.34 +0.02 (+0.86%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$2.38 +0.04 (+1.71%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
